Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10 GBX | -13.04% | -13.04% | -4.76% |
Apr. 17 | Bivictrix granted FDA orphan drug status for rare cancer treatment | AN |
Apr. 17 | BiVictriX Wins US FDA's Orphan Drug Status for Blood Cancer Treatment | MT |
Valuation
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|
Capitalization 1 | 19.5 | 11.24 | 9.49 | 9.49 | - |
Enterprise Value (EV) 1 | 19.5 | 8.06 | 20.25 | 38.39 | 36.69 |
P/E ratio | -4.9 x | -4.5 x | -0.65 x | -0.45 x | 2.62 x |
Yield | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | 0.95 x |
EV / Revenue | - | - | - | - | 3.67 x |
EV / EBITDA | - | -2.85 x | -1.72 x | -2.13 x | 30.9 x |
EV / FCF | - | - | - | - | - |
FCF Yield | - | - | - | - | - |
Price to Book | - | - | - | - | - |
Nbr of stocks (in thousands) | 66,115 | 66,115 | 82,526 | 82,526 | - |
Reference price 2 | 0.2950 | 0.1700 | 0.1150 | 0.1150 | 0.1150 |
Announcement Date | 3/7/22 | 3/30/23 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|
Net sales 1 | - | - | - | - | 10 |
EBITDA 1 | - | -2.824 | -11.8 | -18.04 | 1.188 |
EBIT 1 | - | -2.975 | -12.21 | -18.48 | 0.718 |
Operating Margin | - | - | - | - | 7.18% |
Earnings before Tax (EBT) 1 | - | -2.971 | -12.2 | -18.6 | 0.431 |
Net income 1 | -2.34 | -2.497 | -11.74 | -17.04 | 2.905 |
Net margin | - | - | - | - | 29.05% |
EPS 2 | -0.0602 | -0.0378 | -0.1780 | -0.2580 | 0.0439 |
Free Cash Flow | - | - | - | - | - |
FCF margin | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - |
Dividend per Share 2 | - | - | - | - | - |
Announcement Date | 3/7/22 | 3/30/23 | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|
Net Debt 1 | - | - | 10.8 | 28.9 | 27.2 |
Net Cash position 1 | - | 3.18 | - | - | - |
Leverage (Debt/EBITDA) | - | - | -0.9119 x | -1.602 x | 22.89 x |
Free Cash Flow | - | - | - | - | - |
ROE (net income / shareholders' equity) | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - |
Assets 1 | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - |
Cash Flow per Share 2 | - | -0.0400 | -0.1800 | -0.2700 | - |
Capex 1 | - | - | 0.22 | 0.24 | 0.25 |
Capex / Sales | - | - | - | - | 2.5% |
Announcement Date | 3/7/22 | 3/30/23 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-4.76% | 12.06M | |
+41.79% | 50.93B | |
-0.56% | 42.12B | |
+49.62% | 42.05B | |
-7.20% | 29.18B | |
+12.59% | 26.02B | |
-21.51% | 18.9B | |
+6.92% | 13.21B | |
+24.91% | 12.17B | |
+29.60% | 12.16B |
- Stock Market
- Equities
- BVX Stock
- Financials BiVictriX Therapeutics Plc